Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20099 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Tomotaka Suzuki und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Lymphoma, Large B-Cell, Diffuse, CD79 Antigens, Central Nervous System Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
This study examined the effect of myeloid differentiation primary response gene 88 mutation L265P ( MYD88 L265P ) and/or cluster of differentiation 79B gene mutation Y196 ( CD79B Y196 ) ( MYD88/CD79B ) on central nervous system (CNS) relapse in 270 patients with newly diagnosed diffuse large B‐cell lymphoma (DLBCL). Over a median follow‐up of 6.65 years, 20 patients experienced CNS relapse. Fifty‐five (20%) patients had MYD88/CD79B mutations, and these mutations were significantly associated with an increased risk of CNS relapse in univariable analysis. The overall median time to CNS relapse was 11.5 months, with relapses continuing beyond 2 years in patients harbouring MYD88/CD79B mutations. These patients had 2‐ and 6‐year cumulative CNS relapse rates of 10.9% and 18.1% respectively. Among patients classified as having low or intermediate risk according to the CNS‐International Prognostic Index (CNS‐IPI), those with MYD88/CD79B mutations exhibited higher CNS relapse rates than those without these mutations (18.8% vs. 1.2%). In contrast, patients with high risk showed high CNS relapse, regardless of the mutation status, suggesting heterogeneous mechanisms underlying CNS relapse. In conclusion, the results of this study suggest that MYD88/CD79B mutations may serve as a predictive marker for CNS relapse in DLBCL, although further validation in additional cohorts is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Pathology and Molecular Diagnosis, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Hematology and Oncology, Nagoya City University West Medical Center, Nagoya, Japan.
- Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
- Department of Pathology, Chita Kosei Hospital, Chita, Japan.
ORCID-Profile: Tomotaka Suzuki, Takashi Kanamori, Takaomi Sanda, Masaki Ri, Shigeru Kusumoto, Shinsuke Iida, Hiroshi Inagaki
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Suzuki, T., Fujii, K., Matsunaga, N., Sasaki, H., Kanamori, T., Asano, A., Kinoshita, S., Narita, T., Masaki, A., Sanda, T., Ri, M., Kusumoto, S., Komatsu, H., Iida, S., & Inagaki, H. (2025). Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.20099
Vancouver
Suzuki T, Fujii K, Matsunaga N, Sasaki H, Kanamori T, Asano A, et al. Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma. British Journal of Haematology. 2025. doi:10.1111/bjh.20099
BibTeX
@article{Suzuki2025,
author = {Suzuki, Tomotaka and Fujii, Keiichiro and Matsunaga, Naohiro and Sasaki, Hirokazu and Kanamori, Takashi and Asano, Arisa and Kinoshita, Shiori and Narita, Tomoko and Masaki, Ayako and Sanda, Takaomi and Ri, Masaki and Kusumoto, Shigeru and Komatsu, Hirokazu and Iida, Shinsuke and Inagaki, Hiroshi},
title = {Impact of MYD88 and/or CD79B mutations on central nervous system relapse in patients with diffuse large B‐cell lymphoma},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20099}
}
EUVIMED